- Home
- EQS vs SCLX Comparison
EQS vs SCLX Comparison
Compare EQS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- SCLX
- Stock Information
- Founded
- EQS 1991
- SCLX 2011
- Country
- EQS United States
- SCLX United States
- Employees
- EQS N/A
- SCLX N/A
- Industry
- EQS Finance Companies
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- SCLX Health Care
- Exchange
- EQS Nasdaq
- SCLX Nasdaq
- Market Cap
- EQS 33.7M
- SCLX 35.7M
- IPO Year
- EQS N/A
- SCLX N/A
- Fundamental
- Price
- EQS $2.25
- SCLX $14.64
- Analyst Decision
- EQS
- SCLX Strong Buy
- Analyst Count
- EQS 0
- SCLX 3
- Target Price
- EQS N/A
- SCLX $367.50
- AVG Volume (30 Days)
- EQS 19.9K
- SCLX 318.8K
- Earning Date
- EQS 01-01-0001
- SCLX 08-13-2025
- Dividend Yield
- EQS N/A
- SCLX N/A
- EPS Growth
- EQS N/A
- SCLX N/A
- EPS
- EQS N/A
- SCLX N/A
- Revenue
- EQS $1,355,000.00
- SCLX $44,236,000.00
- Revenue This Year
- EQS N/A
- SCLX $89.26
- Revenue Next Year
- EQS N/A
- SCLX $203.95
- P/E Ratio
- EQS N/A
- SCLX N/A
- Revenue Growth
- EQS 60.35
- SCLX N/A
- 52 Week Low
- EQS $0.74
- SCLX $3.60
- 52 Week High
- EQS $2.49
- SCLX $39.90
- Technical
- Relative Strength Index (RSI)
- EQS 52.33
- SCLX 37.09
- Support Level
- EQS $2.07
- SCLX $14.80
- Resistance Level
- EQS $2.36
- SCLX $19.41
- Average True Range (ATR)
- EQS 0.11
- SCLX 3.04
- MACD
- EQS -0.03
- SCLX -1.30
- Stochastic Oscillator
- EQS 47.37
- SCLX 2.30
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.